Skip to main content

Table 2 Prognostic factors of survival in univariate analyses

From: Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis

  HR (95% CI) P value
Overall survival
 Disease stage 1.45 (1.01–2.06) 0.041
 T stage 1.36 (0.87–2.13) 0.184
 N stage 1.48 (1.06–2.05) 0.021
 Max. tumor size 1.01 (1.00–1.03) 0.031
 Concurrent chemotherapy 1.50 (0.66–3.42) 0.330
 Age 1.02 (0.99–1.06) 0.217
 Sex 1.27 (0.60–2.70) 0.532
Disease-free survival
 Disease stage 1.56 (1.03–2.38) 0.037
 T stage 1.05 (0.64–1.78) 0.868
 N stage 1.66 (1.14–2.42) 0.009
 Max. tumor size 1.00 (0.98–1.02) 0.937
 Concurrent chemotherapy 1.17 (0.47–2.93) 0.739
 Age 1.01 (0.97–1.06) 0.509
 Sex 1.66 (0.69–3.98) 0.259
Locoregional control
 Disease stage 1.62 (1.04–2.53) 0.033
 T stage 1.17 (0.67–2.03) 0.586
 N stage 1.68 (1.13–2.51) 0.010
 Max. tumor size 1.00 (0.98–1.02) 0.725
 Concurrent chemotherapy 1.26 (0.47–3.35) 0.650
 Age 1.01 (0.97–1.06) 0.608
 Sex 1.67 (0.66–4.20) 0.278
Colostomy free survival
 Disease stage 1.48 (0.95–2.30) 0.082
 T stage 1.30 (0.74–2.30) 0.358
 N stage 1.62 (1.07–2.46) 0.022
 Max. tumor size 1.01 (0.99–1.03) 0.227
 Concurrent chemotherapy 1.26 (0.47–3.36) 0.644
 Age 0.99 (0.95–1.03) 0.533
 Sex 1.04 (0.40–2.69) 0.931
  1. HR hazard ratio, CI confidence interval